BioVie is trading at $1.33 (+10.83%) following promising Phase 2 Long COVID results. - On October 19, Biovie presented data at the American Neurological Association meeting, showing statistically significant improvements in key symptoms like fatigue, post-exertional malaise, and objective cognition in pre-specified patient subgroups. - While the overall trial population did not achieve statistical significance on all endpoints, these subgroup benefits are considered clinically meaningful and support future Phase 3 study design. - The biotech sector also showed strength, with XBI reported up 2.09% in the supplied sector context.